ADARx Pharmaceuticals

The company has no product revenue and faces multiple binary readouts: onvuzosiran Phase 3 topline by end of 2027 and agazisiran mid‑ to 2H 2027 signals in IgAN/C3G and PNH.

While siRNA is a validated modality and early ADARx clinical pharmacology is compelling, outcomes still depend on pivotal data, regulatory review, competitive responses and reimbursement. Until approval and launch trajectories are visible, revenue and FCF are highly unpredictable.